ZORYVE Drug Patent Profile

Which patents cover Zoryve, and when can generic versions of Zoryve launch?

Zoryve is a drug marketed by Arcutis and is included in two NDAs. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-four patent family members in thirteen countries.

The generic ingredient in ZORYVE is roflumilast. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the roflumilast profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zoryve

A generic version of ZORYVE was approved as roflumilast by SENORES PHARMS on October 3^rd, 2018.

Summary for ZORYVE

International Patents:	64
US Patents:	20
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	135
Clinical Trials:	4
Drug Prices:	Drug price information for ZORYVE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZORYVE
What excipients (inactive ingredients) are in ZORYVE?	ZORYVE excipients list
DailyMed Link:	ZORYVE at DailyMed

See drug prices for ZORYVE

Recent Clinical Trials for ZORYVE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	PHASE3
Rao Dermatology	PHASE4
Padagis LLC	Phase 3

See all ZORYVE clinical trials

Pharmacology for ZORYVE

Drug Class	Phosphodiesterase 4 Inhibitor
Mechanism of Action	Phosphodiesterase 4 Inhibitors

Paragraph IV (Patent) Challenges for ZORYVE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZORYVE	Cream	roflumilast	0.3%	215985	1	2023-12-27

US Patents and Regulatory Information for ZORYVE

ZORYVE is protected by forty-six US patents and five FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Arcutis	ZORYVE	roflumilast	FOAM;TOPICAL	217242-001	Dec 15, 2023		RX	Yes	Yes			Y
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-003	Oct 4, 2025		RX	Yes	Yes
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-001	Jul 29, 2022		RX	Yes	Yes			Y
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-003	Oct 4, 2025		RX	Yes	Yes			Y
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-003	Oct 4, 2025		RX	Yes	Yes			Y

EU/EMA Drug Approvals for ZORYVE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Daxas	roflumilast	EMEA/H/C/001179Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,	Authorised	no	no	no	2010-07-05
AstraZeneca AB	Libertek	roflumilast	EMEA/H/C/002399Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.	Withdrawn	no	no	no	2011-02-28
AstraZeneca AB	Daliresp	roflumilast	EMEA/H/C/002398Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.	Withdrawn	no	no	no	2011-02-28

International Patents for ZORYVE

See the table below for patents covering ZORYVE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018282098
Australia	2021214399
Brazil	112019025748
Brazil	112022015104
Canada	3006836

Supplementary Protection Certificates for ZORYVE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0706513	C300462	Netherlands		PRODUCT NAME: ROFLUMILAST, DESGEWENST IN DE VORM VAN HET N-OXIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/10/636/001-003 20100705
0706513	10C0052	France		PRODUCT NAME: ROFLUMILAST, ROFLUMILAST-N-OXYDE ET LES SELS DE CES COMPOSES; NAT. REGISTRATION NO/DATE: EU/1/16/636/001 20100705; FIRST REGISTRATION: EU/1/10/636/001 20100705
0706513	SPC/GB10/040	United Kingdom		PRODUCT NAME: ROFLUMILAST, ROFLUMILAST-N-OXIDE AND THE SALTS OF THESE COMPOUNDS.; REGISTERED: UK EU/1/10/636/001 20100705; UK EU/1/10/636/002 20100705; UK EU/1/10/636/003 20100705
0706513	1090034-8	Sweden		PRODUCT NAME: ROFLUMILAST OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/636/001 20100705
0706513	34/2010	Austria		PRODUCT NAME: ROFLUMILAST UND DIE SALZE DIESER VERBINDUNG; REGISTRATION NO/DATE: EU/1/10/636/001 - EU/1/10/636/003 20100705

Last updated: July 24, 2026

ZORYVE (roflumilast) Market Dynamics and Financial Trajectory: Prescription, Pricing, Competition, and IP/Regulatory Exit Risks

ZORYVE (roflumilast) is an epidermal PDE4 inhibitor launched for plaque psoriasis (topical cream) and later expanded to pediatric use and other approved dermatology indications. Near-term market dynamics hinge on dermatologist adoption curves, payor formulary placement, and competitive displacement from biologics, other topical agents (topical steroids/calcineurin inhibitors), and newer topical pipeline launches. The financial trajectory is shaped by net price durability, contracting intensity, and the pace of indication expansion in the commercial base, tempered by LOE risk from patent expiry and any generic/biosimilar-like entry pathway applicable to small-molecule topicals.

---

What is ZORYVE (roflumilast topical) currently approved for, and how do indications drive sales?

ZORYVE is a roflumilast topical therapy positioned in moderate-to-severe plaque psoriasis management as a non-steroidal option with PDE4-inhibition biology. Commercial impact depends on how payors and prescribers allocate it across severity strata and lines of therapy, including topical-first vs step-up to systemic therapy.

Core approved indications that affect commercial uptake

• Plaque psoriasis (topical cream), including labeling expansion to broader age populations over time (pediatric inclusion influences addressable market size).
• Label-driven use patterns that can change utilization: once-daily dosing supports adherence and persistence relative to higher-frequency topical regimens.

Indication expansion timing and revenue relevance

Sales ramp typically correlates with:

• Dermatology guideline inclusion and payer step therapy flexibility.
• Reduced administrative friction (e.g., prior authorization consistency).
• Broader age coverage increasing denominator prescriptions.

---

How fast did ZORYVE ramp after launch, and what market signals predict its forward trajectory?

A small-molecule topical typically shows:

• Early adoption concentrated in dermatology practices with strong topical prescribing workflows.
• Step-therapy and PA gating that can delay scaling despite clinical positioning.
• Sensitivity to net price after rebates and channel contracting.

Forward-looking demand drivers

• Non-steroidal positioning: payors may prefer it when steroid-sparing is clinically justified or when tolerability issues lead to switching.
• Once-daily convenience: reduces burden versus multi-step regimens.
• Dermatology specialty capture: uptake depends on how often dermatologists switch from entrenched topical steroids.

Forward-looking constraints

• Topical market competitiveness is structurally high: low-cost generics (topical steroids) and entrenched brands compress share through price competition.
• Systemic biologics can substitute for topical regimens as disease severity increases, shifting patient cohorts away from topical reliance.

---

What are the key payer and formulary dynamics for ZORYVE, including rebate pressure and step therapy?

Topicals are heavily shaped by:

• Net pricing through rebate structures.
• Contracted tiers and exclusions.
• Quantity limits and prior authorization rules.

Typical payer levers affecting ZORYVE

• Prior authorization: often tied to “failure of topical steroids,” “steroid intolerance,” or body-area criteria.
• Step therapy: may require trying lower-cost agents before coverage.
• Formulary tier: determines patient out-of-pocket and channel stocking.

What to watch in contracts (market read-through)

• Movement from restrictive to preferred formulary tiers.
• Removal or softening of step-edit criteria for certain patient subsets.
• Changes to therapeutic equivalent lists within topical dermatology.

---

How does ZORYVE compete against topical steroids, calcineurin inhibitors, and PDE4 alternatives?

Competitive displacement depends on payer willingness to cover premium topicals and dermatologist confidence.

Competitive matrix: topical alternatives

• Topical corticosteroids (generics and brands): cost advantage and established utilization.
• Topical calcineurin inhibitors: niche use, often for sensitive areas; less direct displacement if psoriasis plaques are central.
• Other non-steroidal dermatology topicals: competing mechanisms and branded pricing.

PDE4-inhibitor class competition

ZORYVE’s differentiated story is topical PDE4 inhibition. Competitive risk is driven by:

• New topical PDE4 entrants, if any, with pricing and coverage advantages.
• Clinical comparisons that affect prescriber willingness to switch.

---

How do biologics and systemic therapies affect the topical market opportunity for ZORYVE?

Systemic options for plaque psoriasis can reduce the pool of patients who rely on topical monotherapy.

Where systemic therapies substitute

• Patients with extensive disease often move to biologics.
• Rapid escalation pathways reduce persistence for premium topicals if early disease control is not reached.

Where topicals retain share

• Patients with localized disease or those managed with topical-first strategies.
• Steroid-sparing preferences and long-term tolerability concerns.

---

What is ZORYVE’s pricing and net revenue trajectory, and how does discounting affect financial performance?

Topical premium brands often show:

• High gross-to-net spread early in ramp.
• Net stabilization after formulary penetration, or continued pressure if contracts remain restrictive.

Net pricing factors

• Rebates tied to attainment and channel behavior.
• PBM formulary placement and UM edits.
• Volume commitments that can reprice the brand.

Financial trajectory implication

If ZORYVE sustains improved formulary status and reduces PA friction, it can support:

• Net price resilience.
• Higher prescription volumes without disproportionate contracting costs.

If coverage stays restrictive, it can force:

• Higher rebates to maintain access.
• Slower prescription growth and lower trajectory durability.

---

What patent estate protects ZORYVE, and when does exclusivity loss create entry risk?

ZORYVE’s financial path is constrained by IP duration in the US and major markets. For a small molecule topical, infringement and expiration events drive generic entry risk and pricing compression.

What determines the timing of market loss

• Composition-of-matter patents and any later-life cycle patents (formulations, methods-of-use, manufacturing).
• Patent term adjustments and extensions.
• Country-by-country expiration and enforcement outcomes.

Commercial risk model

• Before expiry: launch competitors rely on coverage and clinical differentiation rather than price compression.
• After key expiry: rapid erosion is possible if generic entry is feasible for the dosage form and labeling scope.

(Note: a complete timeline of patent numbers and exact expirations requires a verified Orange Book and patent listing set for roflumilast cream and the specific ZORYVE product code. Without it, an accurate day-level exclusivity schedule cannot be stated.)

---

What is the Orange Book status of ZORYVE, and are there Paragraph IV or other challenge risks?

For US exclusivity risk, Orange Book listings must be mapped to:

• Patent numbers.
• Expiration dates.
• Dosage form and drug product identifiers.
• Any patent challenge filings (e.g., Paragraph IV).

(Note: a complete Orange Book, Orange Book NDA/BLA drug product mapping, and any challenge status requires product-specific listing data that is not included in the provided materials. A definitive status statement would be incomplete.)

---

What litigation or settlement agreements could affect ZORYVE’s market trajectory?

Market outcomes can pivot on:

• Generic or product challenge litigation timing and outcomes.
• Settlement terms that delay entry (reverse payment-style arrangements in some small-molecule cases).
• Narrowing of asserted claims that alters practical entry timing.

(Note: a litigation-accurate assessment requires docket- and settlement-specific data for the ZORYVE family.)

---

How does ZORYVE’s supply and manufacturing footprint affect continuity of supply and revenue?

For topicals, production stability impacts:

• Ability to meet prescription growth.
• Time-to-fill for high-demand markets.
• Risk of product shortages that can suppress share.

Manufacturing risks that influence revenue

• Active ingredient supply constraints.
• Scale-up for commercial batches.
• Quality system disruptions.

(Note: a precise financial impact assessment requires manufacturing and supply chain disclosures tied to ZORYVE.)

---

What does ZORYVE’s commercial performance imply for lifecycle strategy and next-asset prioritization?

Lifecycle strategy for dermatology topicals typically focuses on:

• Label expansions that widen the eligible population.
• Form-factor changes (if available) to expand convenience and adherence.
• Clinical evidence packages that support payer relaxation.

Most common commercial strategy playbooks

• Strengthen payer case for earlier-line use.
• Reduce PA burden with clearer criteria.
• Extend pediatric adoption and physician confidence.

---

How does ZORYVE compare with competing dermatology brands on likely share and pricing pressure?

Competitive comparison framework

Because dermatology topicals compete on formulary access and net price rather than only clinical efficacy, the key differentiators for ZORYVE are:

• Prescriber conversion rate from incumbent topical regimens.
• Net price after rebates and preferred tier placement.
• Persistence and refill behavior in routine plaque psoriasis care.

Likely directionally relevant outcomes

• If net price holds while coverage improves, share gains can outpace gross-to-net dilution.
• If coverage stays restrictive, volume growth may require higher rebates, flattening net revenue growth.

---

Key Takeaways

• ZORYVE’s market dynamics are dominated by payer coverage mechanics (PA, step edits, tier placement) and dermatology adoption curves rather than purely clinical differentiation.
• The financial trajectory depends on net price durability, gross-to-net spread management, and whether label/pediatric expansions broaden the addressable base faster than competitive topical and systemic substitution.
• Long-term revenue visibility is constrained by US and ex-US IP expiry and any challenge-driven entry, which will drive pricing compression once exclusivity ends.
• Near-term share risk comes more from premium-vs-generic tradeoffs and formulary tightening than from immediate therapeutic displacement by systemic biologics, though biologics can reduce the topical patient pool as disease severity increases.

---

FAQs

1) Is ZORYVE a steroid-free alternative, and how does that affect payer coverage?

Steroid-free positioning typically supports insurer tolerance for earlier-line use when step edits require steroid failure or intolerance.

2) What dosing schedule and formulation characteristics influence patient adherence for ZORYVE?

Once-daily topical dosing generally improves persistence relative to higher-frequency regimens and can strengthen refill and TRx trends.

3) Will ZORYVE’s pediatric labeling expansion materially change total addressable market?

Yes, pediatric inclusion expands eligibility and can lift share if payors align coverage criteria with labeling.

4) What generic entry risks exist for roflumilast cream, and when are they most likely?

Generic entry timing tracks with key patent expirations and any Orange Book-identified challenge outcomes tied to the specific listed patents and drug product identifiers.

5) How sensitive are ZORYVE sales to formulary placement changes by PBMs?

Sales are highly sensitive: tier status, PA edits, and quantity limit changes can shift volume quickly, especially for premium topical brands.

---

References

(No sources were provided in the prompt. No citations are included.)

DrugChatter Q&A for ZORYVE

Does zoryve have a generic?
Does zoryve have a biosimilar?
When will zoryve be generic?
How does zoryve compare to the competition?
Why is zoryve so expensive?